Biosion USA, Inc. (Biosion), a global R&D biotechnology company, announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen, Inc., a leader in developing next generation ADCs.
In the joint research effort, Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel ADCs.
"We are excited about our new joint research effort with ImmunoGen, a world-renowned leader in ADCs," said Hugh Davis, Ph.D., chief operating officer, and president of Biosion USA, Inc. "This collaboration will take advantage of the strengths of each company; ImmunoGen
